Cenicriviroc (CVC), a dual antagonist of these chemokines’ receptors, CCR2 and CCR5, has been tested in clinical trials in patients with NASH-associated liver fibrosis. This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.